Merck & Company, Inc. vs Sarepta Therapeutics, Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
4.4
Bearish
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
SRPT
Healthy balance sheet and financial position.
⚠ currently unprofitable (-32% margin).
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
HOLD
Target $21.78 (+1.4%)
23 analysts
Fundamentals
MRK
SRPT
31.5×
Trailing P/E
—
11.5×
Forward P/E
7.2×
13.6%
Profit Margin
-32.5%
76.6%
Gross Margin
-7.4%
—
ROE
-53.5%
4.9%
Revenue Growth
-32.7%
—
Earnings Growth
—
0.28
Beta
0.28
—
Price / Book
—
$277.0B
Market Cap
$2.3B
$73 – $125
52-Week Range
$10 – $65
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →